By PPN News Staff
The FDA approved the Kisqali Femara Co-Pack (ribociclib tablets; letrozole tablets, Novartis) for the treatment of hormone receptor–positive, HER-2–negative (HR+/HER2–) advanced or metastatic breast cancer in postmenopausal women.
The co-pack is the first, and only currently available, combination pack with two prescription products for advanced breast cancer.